Monotherapy Versus Dual Therapy for Initial Treatment for Hypertension

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 600 participants.

Also called NCT00994617

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 600 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT00994617
Other papers using this trial's data
  • Combination Therapy Is Superior to Sequential Monotherapy for the Initial Treatment of Hypertension: A Double-Blind Randomized Controlled Trial Journal of the American Heart Association, 2017-11-18 DOI, PubMed 29151036, PMC5721778 In the PMC Open Access subset under CC BY.

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United Kingdom (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT00994617. Randomized; double masking; primary purpose treatment. Start 2010-01 (registry gives no type); primary completion 2014-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Monotherapy Versus Dual Therapy for Initial Treatment for Hypertension
Acronym
Pathway 1
Condition
Hypertension, Resistant to Conventional Therapy
Condition
Essential Hypertension
Intervention (Drug)
Losartan and hydrochlorothiazide
Intervention (Drug)
Hydrochlorothiazide switched over with Losartan at 8 weeks
Lead sponsor
University of Cambridge (class: other)
Collaborator
British Heart Foundation (class: other)

Record details

Record id
cardio:ct-nct00994617
Content hash
b6082b86dc02361e81007a08e0f55463524318fa2037490ba6877b3aaa6e37c9